Loading...
Market
What will be the market share of the new small molecule pill for sickle cell disease compared to CRISPR-based treatments by the end of 2025?
3
Resolution / Starting Odds
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Market analysis reports from reputable sources
Story
New Small Molecule Pill Offers Safer Treatment for Sickle Cell Disease, Published in Science Magazine
Jul 4, 2024, 06:20 PM
A groundbreaking discovery in the treatment of sickle cell disease has been published in Science Magazine. Researchers have developed a small molecule pill that acts as an epigenetic modifier to inhibit fetal hemoglobin, offering a less dangerous and potentially more accessible alternative to CRISPR genome editing, such as Casgevy. This new approach could open up treatment options globally, reducing the need for toxic conditioning. The study, led by a team including Pamela Ting and Jay Bradner, marks a significant advancement in chemical biology and the development of molecular glue degraders.
View original story
Similar markets
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Outside Top 5 • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%